HealthPro BioVentures LLCAdvisor Agreement • March 31st, 2011 • Oncovista Innovative Therapies, Inc • Pharmaceutical preparations
This letter agreement (this “Agreement”) confirms our understanding with respect to your engagement of HealthPro BioVentures LLC (“HealthPro”) to serve as a non-exclusive “Advisor” with respect to the matters set forth herein to OncoVista Innovative Therapies, Inc. (the “Company”). Capitalized terms not otherwise defined herein shall have the meanings set forth in Section 5.
Media Advertising AgreementMedia Advertising Agreement • March 31st, 2011 • Oncovista Innovative Therapies, Inc • Pharmaceutical preparations • New York
This Agreement (“The Agreement”) is made this 8 th day of Febuary 2011, by and between MJD Media LLC. located at 48 Wall Street, 11th Floor, New York, New York 10005 hereinafter sometimes referred to as Consultant and OncoVista Innovative Therapies, Inc. located at 14785 Omicron Drive, Suite 104 San Antonio, TX 78245-3222 hereinafter sometimes referred to as the Company.
EMPLOYEE EMPLOYMENT AGREEMENTEmployee Employment Agreement • March 31st, 2011 • Oncovista Innovative Therapies, Inc • Pharmaceutical preparations • Texas
THIS EMPLOYEE EMPLOYMENT AGREEMENT (the “Agreement”) is made, entered into, and effective as of November 1, 2010 (“Effective Date”) by and between OncoVista Innovative Therapies, Inc., a Delaware corporation (the “Company”), and Tamas Bakos, an individual (the “Employee”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 31st, 2011 • Oncovista Innovative Therapies, Inc • Pharmaceutical preparations • Texas
THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is made, entered into, and effective as of January 3, 2011 (“Effective Date”) by and between OncoVista Innovative Therapies, Inc., a Delaware corporation (the “Company”), and Michael Moloney, an individual (the “Executive”).
NEW MILLENNIUM PR COMMUNICATIONSPublic Relations/Media Services Contract • March 31st, 2011 • Oncovista Innovative Therapies, Inc • Pharmaceutical preparations
This letter when signed by you confirms retaining New Millennium PR. Com., Inc. (“New Millennium”) as media relations counsel for a 3 month period beginning, Tuesday February 1, 2011. The monthly fee for our public relations/media services for the period stated above will be $4,000.00 per month along with 8, 333 five-year warrants per month to purchase shares of common stock at the current market price at the time of signing of this contract.
CONSULTING AGREEMENTConsulting Agreement • March 31st, 2011 • Oncovista Innovative Therapies, Inc • Pharmaceutical preparations • Texas
This Consulting Agreement (the “Agreement”) dated as of January 3, 2011 is by and between OncoVista Innovative Therapies, Inc., a Nevada corporation (“OncoVista”), and FACT Consulting, LLC, a Texas limited liability company located at 30907 Keeneland Drive, Fair Oaks, Texas 78015 (“Consultant”).
LEASE AGREEMENT BETWEEN LIPITEK INTERNATIONAL, INC., AS LANDLORD, AND ONCOVISTA, INC., AS TENANT DATED JANUARY 3, 2011Lease Agreement • March 31st, 2011 • Oncovista Innovative Therapies, Inc • Pharmaceutical preparations
Lease Date: January 3, 2011 Landlord: Lipitek International, Inc., a Delaware corporation Tenant: Oncovista, Inc., a Delaware corporation Premises: Unit Nos. 1, 2 and 3, containing 5,725 rentable square feet, in the office building commonly known as Texas Research Park (the “Building”), and whose street address is 14785 Omicron Drive, San Antonio, Texas 78245, together with the right to use the Common Areas of the Building. The Premises are outlined on the plan attached to the Lease as Exhibit A. The term “Project” shall collectively refer to the Building, the land on which it is located and the driveways, parking facilities, and similar improvements and easements associated with the foregoing or the operation thereof. Term: 36 full calendar months, plus any partial month from the Commencement Date to the end of the month in which the Commencement Date falls, starting on the Commencement Date and ending at 5:00 p.m. local time on the last day of _______, subject to adjustment and earli
